KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Depreciation & Amortization (CF) (2020 - 2025)

Recursion Pharmaceuticals' Depreciation & Amortization (CF) history spans 6 years, with the latest figure at $19.5 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 50.4% year-over-year to $19.5 million; the TTM value through Dec 2025 reached $83.7 million, up 129.36%, while the annual FY2025 figure was $83.7 million, 129.36% up from the prior year.
  • Depreciation & Amortization (CF) reached $19.5 million in Q4 2025 per RXRX's latest filing, down from $21.0 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $23.8 million in Q2 2025 to a low of $1.4 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $8.2 million, with a median of $6.4 million recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): dropped 5.01% in 2024, then surged 192.35% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $2.2 million in 2021, then skyrocketed by 43.74% to $3.2 million in 2022, then skyrocketed by 135.0% to $7.6 million in 2023, then skyrocketed by 71.47% to $13.0 million in 2024, then surged by 50.4% to $19.5 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Depreciation & Amortization (CF) are $19.5 million (Q4 2025), $21.0 million (Q3 2025), and $23.8 million (Q2 2025).